Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis (Q33576939)

28 July 2017

Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis (English)

1 reference

28 July 2017

0 references

0 references

Fiona C McKay

2

0 references

author name string

Kaushal S Gandhi

1

1 reference

28 July 2017

Eve Diefenbach

3

1 reference

28 July 2017

Ben Crossett

4

1 reference

28 July 2017

Stephen D Schibeci

5

1 reference

28 July 2017

Robert N Heard

6

1 reference

28 July 2017

Graeme J Stewart

7

1 reference

28 July 2017

David R Booth

8

1 reference

28 July 2017

Jonathan W Arthur

9

1 reference

28 July 2017

language of work or name

English

0 references

publication date

5 May 2010

1 reference

28 July 2017

1 reference

28 July 2017

5

1 reference

28 July 2017

5

1 reference

28 July 2017

e10484

1 reference

Creative Commons Attribution 4.0 International

28 July 2017

start time

5 May 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

2D DIGE of the cerebrospinal fluid proteome in neurological diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Alteration of DBP levels in CSF of patients with MS by proteomics analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Sample size and replication in 2D gel electrophoresis studies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

The expression and function of chemokines involved in CNS inflammation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Proteomic analysis of multiple sclerosis cerebrospinal fluid

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Early intervention in multiple sclerosis : better outcomes for patients and society?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Clinical characteristics of responders to interferon therapy for relapsing MS.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Early intervention with immunomodulatory agents in the treatment of multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Eotaxin and the attraction of eosinophils to the asthmatic lung

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Protein alkylation in the presence/absence of thiourea in proteome analysis: a matrix assisted laser desorption/ionization-time of flight-mass spectrometry investigation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Metalloproteinases in biology and pathology of the nervous system.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Proteomic analysis of human cerebral endothelial cells activated by multiple sclerosis serum and IFNbeta-1b.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Impact of replicate types on proteomic expression analysis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Optimal replication and the importance of experimental design for gel-based quantitative proteomics.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Increased CXCL8 (IL-8) expression in Multiple Sclerosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Native and transformed alpha2-macroglobulin in plasma from patients with multiple sclerosis

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

T lymphocytes conditioned with Interferon beta induce membrane and soluble VCAM on human brain endothelial cells.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864746

Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis

31 October 2018

1 reference

12 December 2020

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials

1 reference

12 December 2020

New urinary EPO drug testing method using two-dimensional gel electrophoresis

1 reference

12 December 2020

Albumin depletion of human plasma also removes low abundance proteins including the cytokines

1 reference

12 December 2020

Cytokines and chemokines in cerebrospinal fluid and serum of adult patients with acute disseminated encephalomyelitis

1 reference

12 December 2020

Beneficial effect of interferon-beta treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-beta injection

1 reference

12 December 2020

Difference gel electrophoresis

1 reference

12 December 2020

Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis

1 reference

12 December 2020

Interferon beta induces T-helper 2 immune deviation in MS

1 reference

12 December 2020

Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and

1 reference

12 December 2020

Interferon beta1a therapy changes lipoprotein metabolism in patients with multiple sclerosis

1 reference

12 December 2020

Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta

1 reference

12 December 2020

Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells

1 reference

12 December 2020

IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact

1 reference

12 December 2020

Interferon-beta dose and efficacy: the OPTIMS study

1 reference

12 December 2020

Interferon β-1b modulates MCP-1 expression and production in relapsing–remitting multiple sclerosis

1 reference

12 December 2020

Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients

1 reference

12 December 2020

A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0010484

Identifiers

DOI

1 reference

28 July 2017

0 references

1 reference

28 July 2017

1 reference